Premium
Are nilotinib‐associated vascular adverse events an under‐estimated problem?
Author(s) -
StèveDumont Marie,
Baldin Bernadette,
Legros Laurence,
Thyss Antoine,
Re Daniel,
Rocher Fanny,
Ajmia Florian,
Spreux Anne,
Drici MilouDaniel
Publication year - 2015
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12102
Subject(s) - nilotinib , medicine , adverse effect , incidence (geometry) , risk factor , cardiology , tyrosine kinase , physics , receptor , optics
Vascular adverse events have been reported with nilotinib, a tyrosine kinase inhibitor prescribed for chronic myeloid leukaemia. However, few data specify their incidence, or whether they occur in predisposed patients. Hence, we prospectively studied 30 consecutive patients to assess the frequency of such adverse reactions and determine whether the patients presenting with these adverse events bear predisposing factors. From 3 to 73 months after nilotinib initiation, 10 of the 30 patients experienced vascular events. Three patients of these 10 were devoid of any patent cardiovascular risk factor, except for age. This study points out an occurrence more frequent than expected of vascular adverse events associated with nilotinib (> 30% vs. < 1% in summary of product characteristics), and particularly of vascular events of late onset in patients with no pre‐existing risk factors.